{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.9","value":"35.7"},{"groupId":"OG001","spread":"22.5","value":"73.5"},{"groupId":"OG002","spread":"20.6","value":"147"},{"groupId":"OG003","spread":"21.7","value":"278"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"47"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received any study drug and had evaluable Cmax data.","reportingStatus":"POSTED","timeFrame":"Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.","title":"PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104","type":"SECONDARY","unitOfMeasure":"nM"}